A first of its kind: US FDA-approved nasal spray available for treatment-resistant depression in America
Johnson & Johnson reported that Spravato treated over 100,000 patients in 77 countries worldwide, including roughly 80,000 in ...
Verywell Health on MSN2d
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant Depression
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
Monthly Prescribing Reference3d
Spravato Approved as Monotherapy for Treatment-Resistant Depression
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
Boing Boing on MSN6d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with it
On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
pharmaphorum6d
FDA approves Janssen’s ketamine-based nasal antidepressant
Spravato (esketamine ... not responded adequately to at least two different antidepressants of adequate dose and duration in the current depressive episode. It is estimated that approximately ...
ERR News4d
Estonian psychiatrists want to update use of psychedelics in mental health care
A group of Estonian psychiatrists and civic activists believe that allowing the therapeutic use of currently prohibited ...
pharmaphorum3d
Beckley builds case for its psychedelic depression therapy
According to Beckley, BPL-003 achieved an antidepressant response after a single intranasal dose – administered ... in 2019 of Johnson & Johnson’s Spravato (intranasal esketamine) for TRD ...
Medical News Today3d
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
FDA approves Spravato nasal spray as a standalone treatment for depression in adults
The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.
Renal & Urology News4d
FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression
Drug is the first and only approved monotherapy for refractory major depressive disorder. (HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...